Orally delivered, pH-resistant dual coated extracellular vesicles restore intestinal barrier function and suppress colitis - PubMed
6 hours ago
- #Inflammatory bowel disease
- #Oral drug delivery
- #Extracellular vesicles
- Development of a dual-coated oral delivery platform for IBD treatment using macrophage-derived EVs.
- EVs were coated with a cationic lipid and sodium alginate (SA) to encapsulate 5-aminosalicylic acid (5-ASA).
- The coating strategy provided resistance to gastrointestinal stress and enabled targeted drug release in the colon.
- In vitro studies showed enhanced epithelial uptake and macrophage delivery with dual-coated EVs (DCEVs).
- In vivo results demonstrated recovery of colon length, restoration of tight junctions, and reduced inflammation in a DSS-induced colitis model.
- The approach combines EV-mediated immunomodulation with pharmacologic therapy for localized IBD treatment.